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Depression and anxiety and their association with
healthcare utilization in pediatric lupus and mixed
connective tissue disease patients: a cross-sectional
study
Andrea Knight1,2,3,8*, Pamela Weiss1,2,4, Knashawn Morales4, Marsha Gerdes3,5, Allyson Gutstein7,
Michelle Vickery2,3 and Ron Keren2,4,6
Abstract
Background: Depression and anxiety adversely affects outcomes in systemic lupus erythematosus (SLE) and
healthcare utilization is high for pediatric SLE. We aimed to characterize the prevalence of depression and anxiety in
pediatric SLE, and their association with healthcare utilization.
Methods: We conducted a cross-sectional analysis of pediatric SLE and mixed connective tissue disease (MCTD)
subjects and healthy controls aged 8 years and above. We used the Patient Health Questionnaire 9 (PHQ-9) and the
Screen for Childhood Anxiety Related Disorders (SCARED) to identify depression, suicidal ideation and anxiety symptoms,
respectively. We compared symptom prevalence in SLE/MCTD and healthy subjects using logistic regression. For SLE/MCTD
subjects, we calculated the rate of annual outpatient visits [rheumatology/nephrology, primary care provider (PCP) and
emergency department], hospitalizations and rheumatology/nephrology telephone consultations in the preceding year. We
compared these outcomes in those with and without depression and anxiety using negative binomial regression.
Results: We identified depression symptoms in 10 (20%) SLE/MCTD and 4 (8%) healthy subjects, representing a
trend towards increased prevalence in unadjusted analysis (OR = 2.9, 95% CI 0.8-9.9, p = 0.09). Adjusted analysis
did not show a significant difference; however, non-white race was a statistically significant independent risk
factor for depression symptoms compared to white race (OR = 5.4, 95% CI 1.1-27.2, p = 0.04). We identified anxiety
symptoms in 11 (22%) SLE/MCTD and 13 (26%) healthy subjects, which was not statistically different. Suicidal ideation
was present in 7 (14%) SLE/MCTD and 2 (4%) healthy subjects, which was a statistically significant difference (OR = 5.4,
95% CI 1.02-28.3, p = 0.047). Of the 34% of SLE/MCTD subjects with any symptoms, only 24% had previous mental health
care. Those with depression symptoms had a statistically significant lower rate of visits to the PCP (IRR = 0.38,
95% CI 0.19-0.76, p < 0.001). Anxiety symptoms were not associated with the healthcare utilization outcomes.
Conclusions: Depression and anxiety symptoms were prevalent, and suicidal ideation significantly more
common in SLE/MCTD than in healthy subjects. Non-white race was an independent risk factor for depression.
Despite prevalent symptoms, there were poor rates of prior mental health treatment, and less frequent PCP visits
among those with depression symptoms. Further investigation of barriers to mental health care and interventional
strategies for symptomatic youth with SLE/MCTD is needed.
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Background
Systemic lupus erythematosus (SLE) and the SLE-like syn-
drome of mixed connective tissue disease (MCTD) are
chronic autoimmune diseases characterized by systemic
multi-organ inflammation, with significant morbidity and
mortality occurring due to the disease and its treatment.
Pediatric-onset SLE and MCTD represent a substantial
portion of the overall disease burden, with approximately
15-20% of cases beginning in childhood at a median age
of onset of 12–13 years [1]. Thus pediatric SLE and
MCTD patients typically experience disease onset in
early adolescence, a critical time in their psychosocial
development of independence, self-identity and skills
necessary for successful transition to adult roles and
relationships [2]. Several studies indicate a high preva-
lence of depression in pediatric SLE [3-10], but fewer
studies have examined anxiety which is often co-morbid
with depression [11]. In pediatric chronic disease such as
asthma, diabetes and inflammatory bowel disease, depres-
sion and anxiety have been shown to result in poorer dis-
ease control, quality of life, school performance and
transition to adult care [12-15]. In adults with SLE,
depression and anxiety are associated with increased
disease activity, decreased medication adherence, and
work productivity [16-19]. These disorders are there-
fore likely to have significant negative impacts on out-
comes for pediatric SLE and MCTD patients if not
addressed.
Healthcare utilization is high for children and adoles-
cents with SLE [16,17,20] and represents an important
outcome in this group. Frequent medical visits for man-
agement of SLE have potential for adverse effects on
school and family functioning [21]. Healthcare utilization
for patients with SLE also comprises a significant eco-
nomic burden on national health care resources [22]. For
example, the mean annual direct cost of caring for a
pediatric SLE patient, including subspecialist and primary
care visits, emergency department (ED) visits and hospi-
talizations, is approximately $15,000, compared to $1000
for pediatric asthma and $10,000 for inflammatory bowel
disease [22]. Given that depression and poorer mental
health are associated with increased healthcare utilization
and costs in adults with SLE [16,17,20] as well as children
with other chronic conditions [23,24], early identification
and treatment of depression and anxiety in children and
adolescents with SLE or MCTD may lead to decreased
healthcare utilization. There are no studies to our know-
ledge, however, specifically looking at the effects of de-
pression and anxiety on healthcare utilization in pediatric
SLE and MCTD.
We used a cross-sectional design to examine the preva-
lence of depression and anxiety and the association of
these disorders with several types of healthcare utilization
in a cohort of pediatric-onset SLE and MCTD patients.
Specifically we aimed to characterize: 1) the prevalence of
depression and anxiety in pediatric SLE and MCTD pa-
tients compared to healthy children and adolescents; and
2) the association of depression and anxiety with annual
outpatient visits, hospitalizations, and telephone consulta-
tions to rheumatology/nephrology providers for SLE and
MCTD patients. We hypothesized that pediatric SLE and
MCTD patients would have a higher prevalence of depres-
sion and anxiety than their healthy peers, and that SLE
and MCTD patients with depression and/or anxiety would
have higher healthcare utilization than those without these
mental health problems.
Methods
Study design, setting & participants
We performed a cross-sectional analysis on a cohort of
pediatric SLE and MCTD subjects and a cohort of
healthy children and adolescents at The Children’s Hos-
pital of Philadelphia (CHOP). SLE and MCTD subjects
were consecutively recruited during routine outpatient
visits to rheumatology and nephrology between June 2012
and May 2013. SLE subjects had a diagnosis of pediatric-
onset SLE (SLE diagnosed prior to the 18th birthday
when > =4 of 11 SLE classification criteria [25] were
fulfilled). MCTD subjects had a diagnosis of MCTD if
they met either Kahn’s or Alarcon-Segovia’s criteria for
MCTD [26] prior to the 18th birthday. Exclusion cri-
teria were as follows: age less than 8 years; limited
English proficiency, cognitive or communication deficit
precluding questionnaire completion; isolated cutane-
ous lupus. Of 67 eligible subjects approached, 50 (75%)
consented to the study. In order to maximally capture
healthcare utilization, we restricted our utilization ana-
lysis to 42 patients with a minimum disease duration
of 6 months from the date of diagnosis, and at least 2
visits to outpatient rheumatology or nephrology clinic
within the 12 months prior to the study. Healthy par-
ticipants were consecutively recruited during routine
outpatient visits to CHOP primary care between Octo-
ber 2013 and May 2014. Exclusion criteria were as fol-
lows: age less than 8 years; limited English proficiency;
cognitive or communication deficit precluding ques-
tionnaire completion; current use of steroids; diagnosis
with a chronic medical condition including diabetes, irrit-
able bowel disease, persistent ashma, cerebral palsy, sickle
cell anemia, cystic fibrosis, cancer, HIV/AIDS, congenital
heart disease, any other chronic autoimmune, hematologic,
pulmonary, renal, gastrointestinal, neurological, or muscu-
loskeletal condition. Of 112 eligible patients approached,
50 (45%) consented to the study. Informed consent was
obtained from all participants and approval from the
Institutional Review Board at the Children's Hospital
of Philadelphia was obtained prior to initiation of the
study.
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Measures of exposure: depression and anxiety
We screened for depression symptoms in the SLE/MCTD
and healthy control cohorts using the Patient Health
Questionnaire −9 (PHQ-9), a 9-item depression screening
module based on the Diagnostic and Statistical Manual IV
(DSM IV) criteria for major depression [27], which has
been validated in the general adolescent population [28].
Each symptom criteria assesses feelings over the previous
2 weeks, and is scored from 0 (not at all) up to 3 (nearly
every day), giving a total score range from 0 to 27. A tenth
item uses the same scoring schema to assess functional
impairment for those patients scoring > =1 on any of the 9
symptom criteria. A categorical scoring algorithm as fol-
lows indicates a positive screen: total score > =5, in
addition to the first 2 items scored as > =2, and the tenth
item scored as > =1. Positive screens with scores of 5–9,
10–14, 15–19 and 20–27 represent mild, moderate, mod-
erately severe and severe depression symptoms, respect-
ively. Suicide risk was assessed via item 9 on the PHQ-9
questionnaire. Scores > =1 for this item were considered
indicative of suicidal ideation, and were also considered a
positive screen for depression symptoms regardless of
total PHQ-9 score; however, these positive screens were
not categorized for depression severity if the total PHQ-9
was <5.
We screened for anxiety symptoms in the SLE/MCTD
and healthy control cohorts using the Screen for Child-
hood Anxiety Related Disorders (SCARED), a 41-item anx-
iety screening tool which has been validated in outpatient
children and adolescents [29]. The items ask about feelings
in the previous 3 months, focusing on five factors: som-
atic/panic, general anxiety, separation anxiety, and social
phobia. Each item has 3 possible answers: “not true or
hardly ever true” (score of 0), “somewhat true or some-
times true” (score of 1), and “very true or often true” (score
of 2). Item scores were summed, with a total > =25 indicat-
ing a positive screen for the presence of anxiety symptoms.
Depression and anxiety screening was performed using
REDCap (Research Electronic Data Capture) electronic
survey and data capture tools hosted at CHOP [30]. Upon
identification of depression or anxiety symptoms, an edu-
cational handout was provided to the family with mental
health care referral information. Identified suicide risk was
addressed with a suicide prevention protocol consisting of
immediate direct questioning of suicidal intent, plan or at-
tempt within the prior week; endorsement of any of these
prompted development of a safety plan and urgent referral
for immediate psychology/psychiatry evaluation.
Measures of outcome: healthcare utilization
For the SLE and MCTD subjects, we calculated utilization
rates for the primary outcome of annual outpatient visits,
and hospitalizations and telephone consultations as sec-
ondary outcomes. Outpatient visits were a composite of
CHOP rheumatology, CHOP nephrology, primary care
provider (PCP) and emergency department (ED) visits to
any healthcare institution. Hospitalizations included those
at any healthcare institution for any reason. Telephone
consultations included phone calls to the CHOP rheuma-
tology or nephrology offices, initiated by the patients or
caregivers, regarding disease-related issues. We included
these telephone consultations because they are a poten-
tially important point of provider contact for clinical as-
sessment, as well as an often unmeasured component of
provider services. We did not include medication refill re-
quests. For those patients with disease duration > =1 year,
we observed healthcare use over a utilization period of one
year preceding the study visit. For those with disease dur-
ation <1 year, we used a utilization period starting after the
diagnosis date and extending to the time of study visit, ex-
cluding healthcare services used at the time of diagnosis.
Electronic REDCap surveys were administered to participant
parents/legal guardians at the time of enrollment to capture
self-reported utilization data. Manual chart review of both
CHOP and outside provider records was used to verify the
reported utilization. The rate of outpatient visits, hospitaliza-
tions and telephone consultations per person-year were ob-
tained by dividing the number of services used by the
number of person-years of observation in the utilization
period.
Demographic variables and disease characteristics
The following variables were collected by survey of the
parents/legal guardians for SLE, MCTD and healthy con-
trol subjects: age, sex, race/ethnicity, highest household
education level, annual household income, quality of life
(QOL) and subject mental health history. Race/ethnicity
was categorized into 3 mutually exclusive groups: white,
black and other (includes Hispanic, Asian/Pacific Islander,
Native American and other). Highest household educa-
tion level was categorized as either 1) less than college
(includes incomplete college or less) or 2) college (includes
completed associate, bachelors or advanced degree) and
above. Annual household income was categorized into 3
groups according to the US national poverty guidelines for
a household maximum of 8 people for the years of study
[31]: less than $40000, $40000 and above, and prefer
not to answer. QOL was measured using the Pediatric
Rheumatology Quality of Life Scale (PRQL), a concise
10-item instrument measuring the core dimensions of
physical and psychological health, with scores ranging
0–30 (higher score indicates poor QOL), which has been
validated in European and US cohorts of pediatric
rheumatology patients [32,33]. Mental health history
(Y/N) included any of the following: a previous psychiatric
diagnosis, use of psychiatric medications or previous
care by a psychiatrist or psychologist in the preceding
12 months.
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The following variables were abstracted from elec-
tronic medical records of SLE and MCTD subjects:
primary insurance type, disease type, disease duration,
disease manifestations, immunosuppressive medications,
physician global assessment score (PGA), SLE disease ac-
tivity and pain score. Primary insurance was categorized
as Medicaid/Medicare, private or other (includes self-pay
and no charge). Disease type was categorized as SLE or
MCTD based on disease criteria as detailed above. Disease
manifestations included the following, as defined by the
American College of Rheumatology (ACR) SLE classifica-
tion criteria and documented by a rheumatology or
nephrology provider at any point in the disease course: cy-
topenia, arthritis, rash, nephritis, serositis, central nervous
system (CNS) disease. Antiphospholipid syndrome (APS)
status was determined according to the 2006 APS
International Consensus Classification Criteria [34].
Immunosuppressive medications included: current use of
hydroxychloroquine, methotrexate, mycophenolate mofe-
til, azathioprine, glucocorticoids and aspirin; and history
of rituximab, cyclophosphamide or dialysis treatment.
Current glucocorticoid use was categorized into 3 groups:
1) no use 2) low-dose (<10 mg daily Prednisone equivalent)
and 3) high-dose (> = 10 mg daily Prednisone equivalent).
The PGA was assessed at the study visit (baseline) and for
all visits to rheumatology in the utilization period, using a
Likert scale ranging from 0 to 10, with higher scores indi-
cating higher disease activity. SLE disease activity was mea-
sured for SLE patients at the study visit (baseline) and for
all visits to rheumatology or nephrology in the utilization
period, using the Safety of Estrogens in Lupus Erythemato-
sus National Assessment (SELENA) modification of the
SLE disease activity index (SLEDAI) [35,36]. Pain score
was assessed at the time of study visit by participant self-
report on a Likert scale of 0 to 10, with higher scores indi-
cating higher pain levels. Physical functioning of SLE and
MCTD subjects was also assessed by survey of the par-
ents/legal guardians using the Child Health Assessment
Questionnaire (CHAQ), a validated 30-item instrument
that measures 8 functional ability domains and calculates a
disability index ranging from 0 to 3 (higher index indicates
more disability) [37,38].
Statistical analyses
We performed all analyses and statistical comparisons
using Stata 13 (Stata Corp., College Station, TX). Means
and standard deviations (SD), medians and interquartile
ranges (IQR), and frequencies were calculated for demo-
graphic and disease-related variables in the healthy control,
full and restricted SLE/MCTD (for utilization analysis)
cohorts. The presence of depression and anxiety symp-
toms were analyzed as binary covariates according to the
above criteria for positive screens on the PHQ-9 and
SCARED, respectively. We calculated prevalence rates for
depression and anxiety in the SLE/MCTD and healthy
control cohorts, and compared the rates between the full
SLE/MCTD and healthy control cohorts using separate
logistic regression analyses for depression and anxiety. We
then conducted separate multivariable logistic regression
analyses for depression and anxiety adjusting for demo-
graphic covariates. The race/ethnicity variable consisted of
2 categories (white and non-white) and the household in-
come variable consisted of 2 categories (<$40000 and > =
$40000, otherwise missing) for the multivariable analyses.
We screened for potential confounders and effect modi-
fiers by analyzing pairwise associations between the covari-
ates and the exposure and outcome variables. To avoid
overfitting, we included in the multivariate models only co-
variates with statistically significant pairwise associations
(p < 0.2) with both the exposure and outcome variables.
We performed a secondary analysis of the prevalence rate
for suicidal ideation. The presence of suicidal ideation was
analyzed as binary covariate according to a positive suicide
risk on the PHQ-9 as described above. We calculated the
prevalence rate for suicidal ideation in the full SLE/MCTD
and healthy control cohorts, and compared the rates be-
tween cohorts using logistic regression analysis. We then
conducted separate multivariable logistic regression ana-
lyses for suicidal ideation adjusting for demographic covar-
iates as described above.
For the SLE/MCTD cohort, we calculated healthcare
utilization rates per person-year with 95% confidence in-
tervals (CI), and examined the association of these rates
with depression and anxiety using separate negative bino-
mial regression models. We conducted separate multivari-
able negative binomial regression analyses for depression
and anxiety, adjusting for demographic and disease char-
acteristic covariates. We screened for potential con-
founders and effect modifiers by analyzing pairwise
associations between the covariates and the exposure
and outcome variables. To avoid overfitting, we in-
cluded in the multivariable model only covariates with
statistically significant pairwise associations (p < 0.2)
with both the exposure and outcome variables. We calcu-
lated standardized utilization rates from the multivariable
analyses and compared them according to depression and
anxiety status. We also performed secondary analyses to
evaluate the outcomes by outpatient visit type (rheumatol-
ogy/nephrology, PCP and ED). Due to the exploratory na-
ture of these secondary analyses, correction for multiple
testing was not applied. Throughout the analysis, all test-
ing was 2-sided, with a threshold for statistical significance
of p < 0.05.
Results
Demographics & disease characteristics
We enrolled 50 SLE/MCTD subjects, of which 43 had
SLE and 7 had MCTD. Subject ages ranged from 9 to 20
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with a median of 16.5 years (IQR 13.0,17.9). Females
comprised 43 (86%) of the subjects. Twenty-three (46%)
were white, 18 (36%) were black and 9 (18%) were of
“other” race/ethnicity. We enrolled 50 healthy controls,
whose ages ranged from 9 to 21 with a median of
13.4 years (IQR 11.4, 15.2). Females comprised 30 (60%)
of the subjects. Thirteen (26%) were white, 26 (52%)
were black and 11 (22%) were of “other” race/ethnicity.
Additional demographic characteristics are shown in Table 1.
For the full SLE/MCTD cohort the most frequent disease
manifestations were cytopenia (84%), arthritis (74%) and
rash (42%). Current immunosuppressive treatment included
mycophenolate mofetil in 25 (50%) and glucorticoids in 34
(68%). The median physican PGA over the utilization period
was 0.5 (IQR 0,1), and the median SLEDAI score was 2
(IQR 0,4). Additional disease characteristics for the full and
utilization SLE/MCTD cohorts are presented in Table 1.
Depression & anxiety prevalence
Depression and/or anxiety symptoms were identified in
17 subjects (34%) in the full SLE/MCTD cohort and 13
(26%) in the healthy control cohort (Table 2). We found a
trend towards increased prevalence of depression symp-
toms in 10 (20%) of SLE/MCTD subjects compared to 4
(8%) of the healthy controls in the unadjusted analysis
(OR = 2.9, 95% CI 0.8-9.9, p = 0.09). After adjusting for the
confounders of age, sex and race, the difference in depres-
sion symptom prevalence between SLE/MCTD subjects
and controls was not statistically significant (OR = 2.7,
95% CI 0.7-10.2, p = 0.15). However, non-white race was a
statistically significant independent risk factor for depres-
sion symptoms compared to white race in the adjusted
model (OR = 5.4, 95% CI 1.1-27.2, p = 0.04). Anxiety symp-
toms were identified in 11 (22%) SLE/MCTD subjects
and 13 (26%) healthy controls, which did not represent
a statistically significant difference in unadjusted ana-
lysis (OR = 0.8, 95% CI 0.3-2.0, p = 0.64). Adjusting for
the confounder of sex in the multivariable analysis also
did not show a statistically significant difference in
anxiety prevalence. Of the 10 SLE/MCTD subjects
with depression symptoms, 7 (70%) had suicidal idea-
tion, representing 14% of the full SLE/MCTD cohort.
In the healthy controls, 2 of the 4 (50%) with depres-
sion symptoms had suicidal ideation, representing 4%
of the healthy control cohort. In unadjusted analysis,
we found a trend towards increased prevalence of sui-
cidal ideation in the SLE/MCTD cohort compared to
the healthy controls (OR = 3.9, 95% CI 0.8-19.8, p = 0.1).
After adjusting for the confounder of race this difference
was statistically significant (OR = 5.4, 95% CI 1.02-28.3,
p = 0.047). None of the SLE/MCTD subjects and one
of the healthy controls required urgent referral for sui-
cidal ideation. Of the subjects who screened positive
for any symptom (depression, anxiety and/or suicidal
ideation), 4 (24%) SLE/MCTD subjects and 1 (8%)
healthy control reported previous mental health care.
Additional mental health characteristics are presented
in Table 2.
Healthcare utilization
We analyzed healthcare utilization over a total of 41
person-years in the restricted SLE/MCTD cohort. As es-
timated from unadjusted negative binomial regression
models, the overall outpatient visit rate per person-year
was 7.9 (95% CI 6.9-9.1). These were comprised of an
average number of visits per person-year of 4.3 (95% CI
3.7-5.0) to rheumatology, 0.4 (95%CI 0.06-2.7) to neph-
rology, 2.6 (95% CI 2.1-3.3) to primary care providers,
and 0.7 (95% CI 0.4-1.3) to the emergency department.
The average number of hospitalizations per person-year
was 0.3 (95% CI (0.1-0.9) and phone consultations to
rheumatology and/or nephrology was 1.7 (95% 1.2-2.5).
In the regression analysis that included depression as the
primary risk factor, we found that patients with depres-
sive symptoms were significantly less likely to attend
outpatient visits compared to those without depressive
symptoms (IRR = 0.67, 95% CI 0.46-0.96, p = 0.03) (Table 3).
Secondary analysis by outpatient visit type showed patients
with depressive symptoms were statistically less likely to at-
tend PCP visits than those without symptoms (IRR = 0.38,
95% CI 0.19-0.76, p < 0.001) (Figure 1A). There was no dif-
ference in the rate of rheumatology/nephrology or ED
visits with regard to depression status. Depressive symp-
toms were also not associated with differences in hospitali-
zations or phone consultations. Multivariable analysis was
not performed for the depression model because we did
not identify potential confounders or effect modifiers for
inclusion. In the regression analysis that included anxiety
as the primary risk factor, we found no difference in the
rate of outpatient visits (overall and by visit type), hospitali-
zations or phone consultations by anxiety status (Table 4,
Figure 1B). For multivariable analysis, education was iden-
tified as a potential confounder and included in the regres-
sion models for all the utilization outcomes. We also found
no difference in the rate of outpatient visits, hospitaliza-
tions or phone consultations by anxiety status in the multi-
variable models (Table 4).
Discussion
This cross-sectional analysis of a cohort of SLE and MCTD
children and adolescents and their healthy peers adds to
the sparse literature on mental health in pediatric SLE. We
present novel data on prevalence rates of depression, anx-
iety and suicidal ideation for children and adolescents with
SLE/MCTD, as well as estimates of the association of de-
pression and anxiety symptoms with healthcare utilization
for this population. Depression and anxiety symptoms were
prevalent, affecting 34% of our cohort, with depression
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Table 1 Subject demographic & disease characteristics
Healthy controls
N = 50
Full SLE/MCTD
Cohort N = 50
Utilization SLE/MCTD
Cohort N = 42
Age in years, median (IQR) 13.4 (11.4,15.2) 16.5 (13.0,17.9) 16.9 (13.0,18.0)
Female, N (%) 30 (60) 43 (86) 38 (90)
Race/Ethnicity, N (%)
Black 26 (52) 18 (36) 15 (36)
White 13 (26) 23 (46) 21 (50)
Other 11 (22) 9 (18) 6 (14)
Highest Household Education, N (%)
Less than college 12 (24) 9 (18) 8 (19)
College and above 38 (76) 41 (82) 34 (81)
Annual Household Income
<$40000 12 (24) 10 (20) 7 (17)
$40000 and above 34 (68) 30 (60) 25 (60)
Prefer not answer 4 (8) 10 (20) 10 (24)
Insurance (N,%) -
Medicaid 20 (40) 17 (40)
Private 30 (60) 25 (60)
PRQL, median (IQR) 2.5 (1,5) 1 (0, 4) 1 (0,4)
Diagnosis, N (%) -
SLE 43 (86) 37 (88)
MCTD 7 (14) 5 (12)
Disease Duration in months,
median (IQR)
- 23 (11,50) 35 (16, 57)
Disease Manifestations, N (%) -
Cytopenia 42 (84) 37 (88)
Arthritis 37 (74) 30 (71)
Rash 21 (42) 21 (50)
Nephritis 6 (12) 4 (10)
Serositis 6 (12) 6 (14)
CNS disease 3 (6) 3 (7)
APS (lab only) 7 (14) 7 (17)
APS (lab and clinical) 3 (6) 3 (7)
Medications/Treatments, N (%) -
Hydroxychloroquine 49 (98) 41 (98)
Methotrexate 11 (22) 9 (21)
Mycophenolate Mofetil 25 (50) 20 (48)
Azathioprine 2 (4) 2 (5)
Glucocorticoids*
None 16 (32) 15 (36)
Low-dose 28 (56) 25 (59)
High-dose 6 (12) 2 (5)
Aspirin 19 (38) 17 (40)
History of rituximab 7 (14) 7 (17)
History of cyclophosphamide 8 (16) 7 (17)
History of dialysis 1 (2) 0 (0)
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symptoms in 20%, anxiety in 22% and suicidal ideation in
14%. These estimates are similar to previous studies of
pediatric patients with SLE that indicate a prevalence of 15-
55% for depression and 15-20% for anxiety [3-10]. The eti-
ology of depression and anxiety in pediatric SLE and
MCTD patients is likely complex and related several factors
including: the psychological stress of dealing with a chronic
illness during adolescence [39]; inflammatory central ner-
vous system (CNS) pathology related to SLE [40]; direct
steroid CNS effects [41] and indirect steroid-related som-
atic effects (eg. appearance concern due to weight gain,
acne and striae) [42], as well as; hereditary and environ-
mental factors [16,18,43].
In comparison to their healthy peers, there was a
trend towards higher depression symptom prevalence
in SLE/MCTD patients in unadjusted analysis; how-
ever, our adjusted analysis (for age, sex and race) did
not show a significant difference. There was also no
significant difference in anxiety symptom prevalence.
These findings suggest that SLE and MCTD do not
convey additional depression and anxiety risk from the
disease itself. It is notable, however, that our SLE/
MCTD cohort had a low occurrence of diagnosed CNS
disease (6%) and low SLE disease activity. Although
the relationship of depression and anxiety to SLE disease
activity remains unclear in the literature [7,9,18,40,43-46],
it is possible that our findings underestimate depression
and anxiety prevalence in pediatric SLE populations with
higher disease activity. Our results must be interpreted
cautiously, however, as it is difficult to make causal associ-
ations and generalizable conclusions based on our cross-
sectional analysis of a single cohort. We also did not
evaluate additional potential risk factors such as ster-
oid treatment, psychological stress, parental mental health
and family stress in our limited study; inclusion of these
covariates would likely be useful in larger studies.
Table 1 Subject demographic & disease characteristics (Continued)
Baseline SLEDAI**, median (IQR) - 2 (0, 4) 2 (0, 4)
SLEDAI in past year**, median (IQR) - 2 (0, 4) 2 (0, 4)
Baseline PGA**, median (IQR) - 0 (0, 1) 0 (0,1)
PGA in past year, median (IQR) - 0.5 (0, 1.5) 0.5 (0,1)
Pain Score**, median (IQR) - 0 (0, 0) 0 (0,0)
CHAQ Score**, median (IQR) - 0 (0, 0) 0 (0,0)
Demographic and disease characteristics are presented for the healthy control and SLE/MCTD cohorts. *Low-dose glucocorticoid is <10 mg and high-dose is > =10 mg
daily Prednisone equivalent. **Missing data is as follows: PRQL in 11 subjects; baseline SLEDAI in 4 SLE subjects and median SLEDAI in past year in 1 SLE subjects due to
unavailability of laboratory data; baseline PGA in 1 subject; CHAQ in 10 subjects; pain score in 6 subjects.
Table 2 Subject mental health characteristics: depression, suicidal ideation & anxiety prevalence
Healthy
N = 50
SLE/MCTD
N = 50
OR (95% CI) p-value
Unadjusted Adjusted
Depression, N (%) 4 (8) 10 (20) 2.9 (0.8-9.9) p = 0.09 2.7 (0.7-10.2) p = 0.15
Anxiety*, N (%) 13 (26) 11 (22) 0.8 (0.3-2.0) p = 0.64 0.7 (0.2-1.7) p = 0.38
Suicidal Ideation, N (%) 2 (4) 7 (14) 3.9 (0.8-19.8) 0.10 5.4 (1.02-28.3) p = 0.047
Any symptom (depression and/or anxiety*), N (%) 13 (26) 17 (34) - -
PHQ-9 score in depressed, mean (SD) 14 (6) 11 (5) - -
Depression Symptom Severity, N (%)
Mild 0 (0) 5 (10)
Moderate 2 (4) 2 (4)
Moderately Severe 0 (0) 2 (4)
Severe 1 ((2) 1 (2)
SCARED score in anxious, mean (SD) 33 (8) 34 (7) - -
Co-morbid depression & anxiety, N (%) 3 (6) 3 (6) - -
Mental Health History (N,%) 5 (10) 5 (10) - -
Mental Health History in those with any symptom, N (%) 1 (8) 4 (24) - -
The prevalence of depression, anxiety and suicidal ideation symptoms, and other mental health characteristics of the healthy control and full SLE/MCTD cohorts
are shown. The logistic regression model for depression was adjusted for age, sex and race. The logistic regression model for anxiety was adjusted for sex. The
logistic regression model for suicidal ideation was adjusted for race. Depression symptom severity was categorized according to the following PHQ-9 score ranges:
mild 5–9; moderate 10–14; moderately severe 15–19; and severe 20–27. Two subjects screened positive for suicidal ideation and therefore depression, but were
not categorized for depression. *Missing data is as follows: SCARED in 1 SLE/MCTD patient (2%).
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Table 3 Results of the unadjusted negative binomial regression analysis of healthcare utilization on depression
Outcome Average utilization per person-year, number (95% CI) IRR (95% CI)
p-valuePositive depression Negative depression
Outpatient visits 5.7 (4.0-7.9) 8.5 (7.3-9.8) 0.67 (0.46-0.96) 0.03
Hospitalizations 0.1 (0.01-2.5) 0.3 (0.1-1.1) 0.38 (0.01-9.92) 0.56
Phone consultations 1.0 (0.4-2.5) 1.9 (1.3-2.8) 0.52 (0.19-1.41) 0.20
Estimates of healthcare utilization by depression status from unadjusted negative binomial regression analysis models are shown.
A
B
Figure 1 Unadjusted utilization estimates by outpatient visit type according to depression status. A Unadjusted utilization estimates by
outpatient visit type according to depression status are shown. Visit types include rheumatology/nephrology, primary care provider (PCP) and
emergency department (ED). Patients with depressive symptoms were statistically less likely to attend PCP visits than those without symptoms
(IRR = 0.38, 95% CI 0.19-0.76, p < 0.001). Error bars represent 95% confidence intervals. B Unadjusted utilization estimates by outpatient visit type
according to anxiety status are shown. Visit types include rheumatology/nephrology, primary care provider (PCP) and emergency department
(ED). There were no significant differences in outpatient visit types according to anxiety status. Error bars represent 95% confidence intervals.
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Nevertheless, the fact that depression and anxiety symp-
toms affected 34% of our cohort warrants the attention of
pediatric rheumatologists to these common conditions
which are likely to have an adverse impact on outcomes
for pediatric SLE patients. Depression and anxiety are
shown to result in poorer disease control, quality of life,
school performance and transition to adult care in other
pediatric chronic disease such as asthma, diabetes and in-
flammatory bowel disease [12-15]. Furthermore, adults
with SLE and depression/anxiety have associated poorer
medication adherence, increased disease activity and lower
work productivity [16-19]. Thus focusing on identification
and intervention of depression and anxiety in children
and adolescents with SLE could result in earlier treatment
and better patient-oriented outcomes.
Of significant concern is our finding of suicidal idea-
tion in 14% of our SLE/MCTD subjects, which showed a
statistically significant increased prevalence compared to
4% of the healthy controls. The literature is scarce for
suicidal ideation in pediatric SLE. Nassi et al. reported
suicidal ideation in up to 19% of their pediatric SLE pa-
tients [47]. Lim et al. reported suicidal ideation in 34%
of 53 pediatric patients with neuropsychiatric SLE, and
20% of those with ideation attempted suicide [48]. In
contrast, Kohut et al. reported no suicidal ideation in a
cohort 38 children and adolescents with SLE, of which
26% had depression symptoms [9]. However, studies in
adults with SLE show suicidal ideation is common in up
to one-third of patients with and without neuropsychi-
atric SLE [49,50], and is associated with higher disease
activity, increased depression and anxiety severity and
previous suicide attempts [51]. Although none of our
SLE/MCTD subjects with suicidal ideation posed an im-
mediate suicide risk, our results build on the data sup-
porting a need for increased awareness and ability to
identify and intervene for suicidal ideation in pediatric
patients with SLE/MCTD.
Given the levels of depression, anxiety and suicidal idea-
tion, it is concerning that only 24% of subjects in our
cohort with any of these symptoms reported previous
mental health care. There are several possible reasons
occurring at the patient, caregiver, provider and healthcare
system levels that may be contributing. At the patient
level, non-white race was a statistically significant inde-
pendent risk factor for depression symptoms compared to
white race in our cohort. This is of particular importance
for pediatric SLE patients who are a disproportionately
non-white group [1]. The reason for this increased risk
is unclear but may be related to known cultural stigma
and socioeconomic barriers to diagnosing and man-
aging depression in those of non-white race [52-54].
This has implications for ensuring appropriate depres-
sion identification and access to treatment of youth
with SLE.
At the provider level, mild symptoms may be overlooked
as part of normal adolescent development; however, persist-
ent mild or “subthreshold” depression symptoms in adoles-
cence are a predictor of development of major depression
and suicidal behavior in later adulthood [55,56] and should
be evaluated. Despite the availability of validated screening
tools and evidence-based therapies for depression and anx-
iety [57-60], pediatric rheumatologists may feel ill-equipped
to address the mental health needs of children and adoles-
cents with SLE/MCTD. Recent national efforts have estab-
lished the role of PCPs in screening and intervention for
adolescent depression as part of a collaborative care model
[61], but rheumatologists are often the principal providers
for SLE patients [62], and may be better-suited for this role.
Our outpatient utilization data supports this as our SLE/
MCTD cohort visited their rheumatologists almost twice as
much as their PCPs, affording the most opportunity to
pediatric rheumatologists for addressing their mental health
needs. Our finding that SLE/MCTD patients with depres-
sion symptoms visited their PCPs approximately 60% less
frequently than those without symptoms suggests a poten-
tially wider differential between PCP and rheumatology con-
tact in those with depression. One might speculate that
depressed children and adolescents and potentially concur-
rently depressed caregivers might exhibit negative coping
styles and social withdrawal [63], resulting in less PCP con-
tact but preserved visits to rheumatologists as their principal
providers. Potential system level barriers to the implementa-
tion of screening and intervention in pediatric rheumatology
practice including costs, reduced clinic efficiency and lack of
Table 4 Results of the unadjusted and adjusted negative binomial regression analyses of healthcare utilization on
anxiety
Outcome Unadjusted analysis Adjusted analysis
Average utilization per person-year,
number (95% CI)
IRR (95% CI)
p-value
Average utilization per person-year,
number (95% CI)
IRR (95% CI)
p-value
Positive anxiety Negative anxiety Positive anxiety Negative anxiety
Outpatient visits 8.2 (6.1-11.0) 7.9 (6.7-9.3) 1.03 (0.74-1.44) 0.84 11.4 (7.4-17.7) 10.0 (7.6-13.3) 1.14 (0.82-1.59) 0.45
Hospitalizations 0.2 (0.02-2.9) 0.3 (0.1-1.2) 0.70 (0.04-12.5) 0.81 5.8 (0.2-147.3) 1.1 (0.2-5.2) 5.1 (0.3-88.7) 0.26
Phone consultations 2.3 (1.2-4.7) 1.6 (1.1-2.4) 1.44 (0.64-3.22) 0.38 4.9 (1.7-14) 2.7 (1.4-5.3) 1.84 (0.8-4.1) 0.14
Estimates of healthcare utilization by anxiety status from negative binomial regression analysis models are shown. Multivariable analyses include education level
as a covariate, and standardized estimates are presented for subjects with highest household education level of college and above.
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behavioral health resources, deserve further investigation.
Additionally, other associations between depression/anxiety
and other healthcare utilization outcomes may exist with
implications for mental health care treatment, but our study
may be underpowered to detect them in our limited sample.
Our results therefore serve to generate hypotheses for larger
studies and longitudinal investigation of the relationship be-
tween depression/anxiety and healthcare utilization for chil-
dren and adolescents with SLE/MCTD. Nonetheless, our
findings highlight the fact that there are no existing guide-
lines or standard practices for mental health screening and
intervention of depression, anxiety and suicidal ideation
for pediatric SLE and MCTD patients in the context of
pediatric rheumatology care.
Conclusions
Depression and anxiety symptoms were prevalent, and sui-
cidal ideation significantly higher in this cohort pediatric
SLE and MCTD patients compared to their healthy peers.
Non-white race was an independent risk factor for depres-
sion symptoms with implications for access to mental
health care for youth with SLE, who represent a dispropor-
tionately non-white group. Despite mental health symp-
toms affecting one third of the cohort, rates of prior
mental health treatment were poor, and PCP visits were
less frequent among those with depression symptoms. Our
results suggest an important role for pediatric rheumatolo-
gists in addressing mental health in symptomatic youth
with SLE/MCTD. There is a need for increased awareness
and further investigation of the barriers to mental health
care and strategies for improving the mental health of
pediatric SLE and MCTD patients.
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